Related Experiment Video
Updated: Aug 22, 2025
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease
Qianqian Yang1, Wenjia Xie1, Xiao Wang1
1Center for Kidney Disease, 2nd Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Abstract:
Diabetic kidney disease (DKD) is currently one of the leading causes of end-stage renal disease (ESRD). Mitochondrial dysfunction in podocyte is involve in DKD development. However, whether early mitochondrial stabilization delays or reverses DKD progression has not been elucidated. SS31 is a novel tetrapeptide compound that targets the inner mitochondrial membrane and protects mitochondria by reducing ROS and inhibiting cardiolipin oxidation. Our study discovered that SS31 might have a long-term podocyte protection in DKD. In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes. Results revealed that podocyte mitochondrial injury appeared at the early stage of DKD. Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1. Those data indicate that SS31 might be a promising agent in delaying the development of DKD and OMA1-mediated hydrolysis of OPA1 in mitochondria, and SS31 is a novel therapeutic target for the treatment of DKD.
Insights
Early intervention with SS31 protects podocytes and kidney function in diabetic kidney disease (DKD). This mitochondrial stabilization delays DKD progression by inhibiting OMA1-mediated OPA1 hydrolysis, suggesting SS31 as a novel therapeutic target.
Area of Science:
- Nephrology
- Mitochondrial Biology
- Diabetology
Background:
- Diabetic kidney disease (DKD) is a major cause of end-stage renal disease (ESRD).
- Podocyte mitochondrial dysfunction is implicated in DKD pathogenesis.
- The potential of early mitochondrial stabilization to halt DKD progression remains unclear.
Purpose of the Study:
- To investigate the protective effects of SS31, a mitochondrial-targeting tetrapeptide, on podocytes in DKD.
- To determine if early SS31 treatment can delay or reverse DKD progression.
- To elucidate the underlying mechanism involving OMA1-mediated OPA1 hydrolysis.
Main Methods:
- Assessment of glomerular pathological damage and proteinuria at various diabetes stages.
- Evaluation of podocyte mitochondrial injury.
- Analysis of SS31's impact on OMA1-mediated OPA1 hydrolysis in mitochondria.
Main Results:
- Podocyte mitochondrial injury was observed at the early stages of DKD.
- Early administration of SS31 demonstrated significant podocyte protection.
- SS31 treatment alleviated DKD development by inhibiting OMA1-mediated OPA1 hydrolysis.
Conclusions:
- Mitochondrial dysfunction in podocytes occurs early in DKD.
- SS31 shows promise in delaying DKD progression through mitochondrial protection.
- Targeting OMA1-mediated OPA1 hydrolysis with SS31 represents a novel therapeutic strategy for DKD.
Related Concept Videos
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...